Skip to Content
Merck
All Photos(1)

Key Documents

More Documents

15236

Sigma-Aldrich

N,O-Bis(trimethylsilyl)carbamate

≥98.0% (T)

Synonym(s):

BSC, Trimethylsilyl N-(trimethylsilyl)carbamate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Linear Formula:
(CH3)3SiNHCO2Si(CH3)3
CAS Number:
35342-88-2
Molecular Weight:
205.40
Beilstein:
2043399
EC Number:
252-520-4
MDL number:
MFCD00040476
UNSPSC Code:
12352100
PubChem Substance ID:
329750791
NACRES:
NA.22

Quality Level

100

Assay

≥98.0% (T)

form

solid

mp

77-83 °C

SMILES string

C[Si](C)(C)NC(=O)O[Si](C)(C)C

InChI

1S/C7H19NO2Si2/c1-11(2,3)8-7(9)10-12(4,5)6/h1-6H3,(H,8,9)

InChI key

DGIJAZGPLFOQJE-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Other Notes

Extremely suitable reagent for the silylation of alcohols, phenols and carboxylic acids. The only by-products are CO2 and NH3; Silyloxycarbonylation of amines; Acylisocyanates from carboxylic acid chlorides

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
048627/1V
048627/1
048627/1V
48627/1
048627/1

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

L. Birkofer et al.
Journal of Organometallic Chemistry, 99, C1 (1975)
Sudarshan Chari et al.
PLoS genetics, 9(8), e1003661-e1003661 (2013-08-13)
The phenotypic outcome of a mutation cannot be simply mapped onto the underlying DNA variant. Instead, the phenotype is a function of the allele, the genetic background in which it occurs and the environment where the mutational effects are expressed.
Yoshitaka Narita et al.
Neuro-oncology, 21(3), 348-359 (2018-12-01)
We conducted a phase III trial of personalized peptide vaccination (PPV) for human leukocyte antigen (HLA)-A24+ recurrent glioblastoma to develop a new treatment modality. We randomly assigned 88 recurrent glioblastoma patients to receive PPV (n = 58) or the placebo
M J Sorich et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 26(1), 13-21 (2014-08-15)
Monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR) prolong survival in metastatic colorectal cancer (mCRC) Kirsten rat sarcoma viral oncogene (KRAS) exon 2 wild-type tumors. Recent evidence has suggested that other RAS mutations (in exons 3 and 4
Ronak Saluja et al.
Journal of oncology practice, 14(5), e280-e294 (2018-03-31)
The purpose of this study was to determine if clinical benefits of novel anticancer drugs, measured by the ASCO Value Framework and European Society of Medical Oncology (ESMO) Magnitude of Clinical Benefit Scale, have increased over time in parallel with
View All Related Papers

Articles

Silylation of Non-Steroidal Anti-Inflammatory Drugs

Results of a study involving the ability few Fluka silylating reagents to form GC-MS-compatible trimethylsilylmethyl derivatives of NSAIDs

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service